Bacil Pharma

Bacil Pharma’s board, at a meeting on 9 July 2026, approved raising up to ₹50 crore through a rights issue of equity shares to existing shareholders. The company also decided to increase its authorised share capital by ₹45 crore, from ₹20 crore to ₹65 crore, and appointed Purva Sharegistry as registrar, Axis Bank as banker to the issue, and Acuite Ratings & Research as the monitoring agency. The board accepted the resignations of independent directors Dinesh Chander Notiyal and Avani Savjibhai Godhaniya and formed a rights issue committee chaired by executive director and CFO Chaitali Kalpataru Shah. The detailed terms — issue price, rights entitlement ratio, and record date — will be determined later, and the issue remains subject to regulatory and shareholder approvals.

Powered by Tijori

July 9 (Reuters) - Bacil Pharma Ltd BACP.BO:

• BACIL PHARMA - APPROVES RIGHTS ISSUE OF EQUITY SHARES FOR UP TO 500 MILLION RUPEES

Source text: ID:nBSE4LFfYc

Further company coverage: BACP.BO

(([email protected];;))

July 3 (Reuters) - Bacil Pharma Ltd BACP.BO:

• BACIL PHARMA - TO CONSIDER RIGHTS ISSUE OF EQUITY SHARES UP TO 500 MILLION RUPEES

Source text: ID:nBSE8KxF3M

Further company coverage: BACP.BO

(([email protected];))

Niraj Rajnikant Shah, a Mumbai-based investor, has acquired a 6.44% stake in Bacil Pharma through open-market purchases, according to a regulatory filing on June 25. Shah bought 925,000 shares over three trading days from June 22 to June 24, taking his holding from zero to 6.44% of the nano-cap pharmaceutical company. The acquisition follows a series of stake sales by other non-promoter shareholders, including Manubhai Shah and Nikita Patel, who reduced their holdings earlier in June. Bacil Pharma, with a market capitalisation of about ₹57 crore, reported zero operating revenue for the year ended March 2026.

Powered by Tijori

Bacil Pharma's board approved a proposal to raise up to ₹50 crore through one or more equity or equity-linked instruments, the nano-cap pharmaceutical company said on Friday. The fundraising, which could include a rights issue, preferential allotment, convertible securities or warrants, is subject to regulatory and shareholder approvals. The board authorised senior management to evaluate options, appoint intermediaries and finalise the structure, with the exact size, pricing and terms to be determined later. The announcement came days after disclosures showed significant stake sales by non-promoter shareholders in the same period. Bacil Pharma, with a market capitalisation of about ₹57 crore, has reported zero operating revenue and relies on other income. The decision to seek funds equal to nearly its entire market value is a potentially transformative move for the company.

Powered by Tijori

June 26 (Reuters) - Bacil Pharma Ltd BACP.BO:

• BACIL PHARMA - BOARD APPROVES FUNDRAISING OF UP TO 500 MILLION RUPEES VIA VARIOUS MODES, SUBJECT TO APPROVALS

Source text: ID:nBSEc9sB2n

Further company coverage: BACP.BO

(([email protected];))

Manubhai Amrutlal Shah, a non-promoter large shareholder of Bacil Pharma, sold 394,893 shares, or 2.75% of the company's equity, in two open-market transactions on June 23 and 24, 2026. The sales reduced his holding from 12.77% to 10.02%. The disposal comes just two weeks after the same shareholder had sold a 5.57% stake, bringing his total selling in June to over 8% of the company. Bacil Pharma, with a market capitalisation of about ₹60 crore, has reported zero operating revenue.

Powered by Tijori

Nikita Hiren Patel, a substantial non-promoter shareholder in Bacil Pharma, sold 7.10% of the company's equity through open-market transactions on June 22 and 23, 2026. The sale of 1,019,052 shares reduced her stake from 17.17% to 10.07%. The transaction follows a separate 2.27% stake sale by the same investor earlier in June. Bacil Pharma, with a market capitalisation of about ₹60 crore, has reported zero operating revenue.

Powered by Tijori

June 23 (Reuters) - Bacil Pharma Ltd BACP.BO:

• BACIL PHARMA - BOARD TO CONSIDER FUND RAISING

Source text: ID:nBSE1GKrxY

Further company coverage: BACP.BO

(([email protected];))

Nikita Hiren Patel, a non-promoter shareholder in Bacil Pharma, sold 326,104 shares or 2.27% of the company's equity through open-market transactions on June 8 and 9, 2026. The sale reduced her holding from 19.44% to 17.17% of the nano-cap pharmaceutical company's share capital. The transaction was disclosed to the Bombay Stock Exchange on June 10 under SEBI's substantial acquisition and takeover rules. Bacil Pharma, with a market capitalisation of about ₹68 crore, has reported zero operating revenue in recent periods and relies on other income.

Powered by Tijori